Back to search
Hypochondroplasia
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Hypochondroplasia trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Hypochondroplasia trials you may qualify forThe purpose of this study is to evaluate the safety and efficacy of daily administration of vosoritide in participants with HCH aged 0 to \< 36 months over a 52…
The study aims to identify which Syde®-derived digital outcomes are reliable in FGFR3-related Skeletal Dysplasia. This requires to set-up a natural history stud…
This is a long-term, multicenter, non-interventional study of children ages 2.5 to \<17 years with hypochondroplasia (HCH).
This study will assess growth over time and the clinical course of HCH in children by collecting growth measurements and other variables of interest.
This registry is a observational, single-center study designed to collect clinical data on patients with achondroplasia and hypochondroplasia.
Short stature can be caused by a number of genetic etiologies, many of which directly affect the growth plate. The FGFR3/CNP pathway is central to growth of the…
Phase 2, multicenter, OLE study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR (fibroblast growth factor receptor) 1-3-se…
The intent and design of this Phase 3 study is to assess vosoritide as a therapeutic option for the treatment of children with hypochondroplasia (HCH).